Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
VERVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 12.79 USD | -0.93% | +8.48% | -33.90% | |
| Dec. 01 | Verve Therapeutics Closes Public Offering of Common Shares | MT |
| Dec. 01 | Verve Therapeutics, Inc. announced that it has received $22.96317 million in funding from Eli Lilly and Company | CI |
Financials (USD)
| Sales 2023 * | 7.82M | Sales 2024 * | 9.79M | Capitalization | 1.03B |
|---|---|---|---|---|---|
| Net income 2023 * | -206M | Net income 2024 * | -235M | EV / Sales 2023 * | 75,6x |
| Net cash position 2023 * | 438M | Net cash position 2024 * | 226M | EV / Sales 2024 * | 82,0x |
| P/E ratio 2023 * | -3,89x | P/E ratio 2024 * | -3,76x | Employees | 204 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 91.86% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.93% | ||
| 1 week | +8.48% | ||
| Current month | +13.39% | ||
| 1 month | -18.54% | ||
| 3 months | +1.43% | ||
| 6 months | -25.60% | ||
| Current year | -33.90% |
1 week
11.36
13.43
1 month
8.2213.43
Current year
8.2224.69
1 year
8.2224.69
3 years
8.2278.00
5 years
8.2278.00
10 years
8.2278.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sekar Kathiresan
FOU | Founder | 51 | 2017 |
Allison Dorval
DFI | Director of Finance/CFO | 47 | 2021 |
Andrew D. Ashe
PSD | President | 56 | 2018 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Burt A. Adelman
FOU | Founder | 70 | 2017 |
Lonnel Coats
BRD | Director/Board Member | 58 | 2022 |
| Director/Board Member | 57 | 2021 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.13% | 2 M€ | -25.75% | ||
| 3.54% | 0 M€ | 0.00% | - | |
| 1.83% | 2 M€ | +1.46% | - | |
| 1.80% | 1,356 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 12.79 | -0.93% | 1,167,334 |
| 23-12-07 | 12.91 | +3.36% | 1,430,684 |
| 23-12-06 | 12.49 | +7.95% | 2,321,449 |
| 23-12-05 | 11.57 | -3.66% | 1,251,848 |
| 23-12-04 | 12.01 | +1.87% | 1,407,080 |
Delayed Quote Nasdaq, December 08, 2023 at 04:00 pm EST
More quotes
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company's programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second product candidate VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a regulator of cholesterol and triglyceride metabolism.
Calendar
2024-03-10
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
12.79USD
Average target price
45.89USD
Spread / Average Target
+258.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.90% | 1 029 M $ | |
| +70.40% | 41 313 M $ | |
| +5.07% | 39 289 M $ | |
| -55.28% | 30 625 M $ | |
| -27.34% | 27 758 M $ | |
| +40.26% | 22 431 M $ | |
| -28.45% | 21 339 M $ | |
| +4.49% | 17 693 M $ | |
| -13.10% | 11 356 M $ | |
| -17.58% | 10 803 M $ |
